President of Israel Shimon Peres Tours Gamida Cell in Jerusalem

Gamida Cell Is a World Leader in Adult Stem Cell Technologies and Products
JERUSALEM--(Business Wire)--
Gamida Cell announced that the President of Israel, His Excellency Shimon Peres
visited the company today for a briefing and a tour of the R&D facility.

The purpose of the visit was for the president to learn more about the stem cell
industry, which he recognizes to be important. Great strides have already been
made in this growing industry, with several new products expected to reach the
market in the next two years. Israel and Gamida Cell are at the forefront of
this progress.

President Peres said, "Your company is not only a leader in cell therapy in
Israel, but also worldwide. My visit today was intriguing; the work done at
Gamida Cell shows that Israel has the greatest minds and scientists. I am proud
that a company like yours represents our best and brightest."

The visit included:

* Stem Cell Industry Overview: Israel and Internationally

Dr. Aharon Schwartz, Vice President, Innovative Ventures, Teva Pharmaceuticals

* Overview of Gamida Cell and its current international Phase III ExCell study
of StemEx for leukemia and lymphoma

Dr. Yael Margolin, President and CEO, Gamida Cell

* Tour of the lab

Tony Peled, Founder and VP R&D

Israel has the second largest number of scientific publications in the stem cell
field; the United States ranks first. Israel is also home to more than 70
academic groups engaged in stem cell research and nearly 20 companies developing
stem cell therapy related products (Office of the Chief Scientist of Israel).
There are around 300 stem cell companies worldwide, and it is estimated that the
market will reach $178M in 2009, $700M in 2010, and $8.5B in 2016 (Robin R.
Young, 2008).

"Gamida Cell is a prime example of Israel`s leadership in stem cell research.
The Gamida Cell-Teva Joint Venture is currently conducting the last stage of its
clinical testing of StemEx, a therapy for patients with blood cancers such as
leukemia and lymphoma who need a bone marrow transplantation. This is the
largest multi-center cord blood transplant study for adults run by a company in
the world," said Dr. Schwartz.

"We were delighted to have the opportunity to host President Peres and to answer
his questions. The Israeli government has always been supportive of the stem
cell industry and of our work. Since the beginning, the Office of the Chief
Scientist has awarded Gamida Cell a total of $12M in grants to develop our
products, including StemEx, which we anticipate will enter the market in 2011,"
said Dr. Margolin.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and
therapeutic products. The company is developing a pipeline of products in stem
cell transplantation and in tissue regeneration to effectively treat
debilitating and often fatal illnesses such as cancer, hematological, autoimmune
and ischemic diseases. Gamida Cell`s therapeutic candidates contain populations
of adult stem cells, selected from non-controversial sources such as umbilical
cord blood and bone marrow, which are expanded in culture. Gamida Cell was
successful in translating these proprietary expansion technologies into robust
and validated manufacturing processes under GMP. Gamida Cell`s flagship product,
StemEx, is now being studied as a therapy for patients with blood cancers in an
international pivotal trial, called ExCell (www.stemexstudy.com), at leading
transplant centers in the U.S., Europe and Israel. StemEx has orphan drug
designation in the U.S. and in Europe. Gamida Cell`s current shareholders
include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva
Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures. Ruben Krupik is the
chairman of the board of Gamida Cell. For more information, please visit:
www.gamida-cell.com. For information regarding the ExCell study:
www.stemexstudy.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5968829&lang=en

Gamida Cell Ltd.
Press contact:
Marjie Hadad, +972-54-536-5220
marjie@gamida-cell.com.

Copyright Business Wire 2009